a Human brains harbor herpes simplex virus type-1 (HSV-1) DNA, which normally remains quiescent throughout many decades of life. HSV-1 is associated with viral encephalopathy and with the amyloid beta 42 (Ab42) peptide-enriched lesions that characterize Alzheimer's disease neuropathology. Here we report that infection of human neuronal-glial cells in primary co-culture with HSV-1 induces an irregular hypertrophy of human neuronal-glial cell bodies, an induction of HSV-1 DNA polymerase, and an up-regulation of micro-RNA-146a associated with altered innate-immune responses. Presence of the antiviral acyclovir or soluble Ab42 peptide significantly attenuated these neuropathological responses. The inhibitory effects of Ab42 peptide were also observed in an HSV-1-infected CV-1 cell-based viral plaque assay. The results suggest that soluble Ab42 peptide can invoke non-pathological and anti-viral effects through inactivation of an HSV-1 challenge to human brain cells by simple viral sequestration, viral destruction, or by complex neurogenetic mechanisms. NeuroReport
Introduction
Herpes simplex virus-1 (HSV-1), a neuroinvasive group 1 member of the herpes virus family Herpesviridae, is known to establish lifelong latency in human nervous tissues [1, 2] . HSV-1 neural activation is associated with viral encephalopathy, through the induction of altered innate immune and inflammatory responses, immunosuppression and neurodegeneration [1] [2] [3] [4] [5] . Although a link between HSV-1 infectivity, latency and Alzheimer's disease has long been suspected, and HSV-1 associates with amyloid-beta 42 (Ab42) peptides that characterize Alzheimer's disease neuropathology, the molecular-genetic mechanism of the HSV-1-Ab42 peptide association is not fully understood [3] [4] [5] [6] [7] .
Micro-RNAs (miRNAs) are small, non-coding RNAs that through base-pair complementarity and hydrogen bonding with their target messenger RNAs (mRNAs) regulate miRNA-mRNA expression networks in health and disease [8] [9] [10] [11] [12] . Brain cells utilize only a specific subset of all known human miRNAs in normal homeostatic neural functions [8, 9] , and misregulation of several brain-enriched miRNAs appear to contribute to neurodegeneration and neurological disease [3, [9] [10] [11] [12] [13] [14] . Specific miRNAs such as miRNA146a have been found to be significantly up-regulated during HSV-1 and other viral infections to function in the regulation of oxidative stress, host inflammatory signaling and innate immunity [8] [9] [10] [11] [12] [13] [14] .
In this study we used human miRNA arrays, Northern dot blot, RT-PCR for HSV-1 DNA polymerase, and viral infectivity assay to examine the effects of the 'classical' antiviral acycloguanosine acyclovir (ACV) and soluble Ab 42 peptide on HSV-1 (17Syn +) infection and miRNA-146a regulation in 2.5-week-old human neuronal-glial (HNG) cells in primary co-culture. The results suggest that both ACV and Ab42 peptide effectively quench neuroinvasiveassociated and neuroinfective-associated actions of HSV-1 and their ensuing pathogenic effects, in part by blocking the HSV-1-mediated induction of miRNA-146a. The results further suggest that the soluble Ab42 peptides are capable of invoking non-pathological and anti-viral effects in sequestering or inactivating an HSV-1 challenge to primary human brain cells, either by simple Ab42 peptide-HSV-1 adsorption and sequestration, viral destruction, or through other complex, yet unidentified, neurogenetic mechanisms.
California, USA). Ab42 peptide and a biologically inactive Ab42 scrambled (Ab42s) control peptide were obtained from American Peptide (Sunnyvale, California, USA) and used at 5 and 100 mM concentrations in cell culture media; acycloguanosine, as ACV was obtained from Sigma-Aldrich (St Louis, Missouri, USA) and used at 30 mM. RNAse-free plasticware and RNAse-free isolation reagents including diethyl pyrocarbonate) water were purchased from Ambion, Invitrogen or SigmaAldrich and were used as described earlier [3, 10] .
Human neuronal-glial cells in primary culture, CV-1 cells and HSV-1 infection HNG cells (CC-2599; Lonza Corporation, Walkersville, Maryland, USA) were cultured in an HNG maintenance medium for 2.5 weeks as described earlier by our group [3, [10] [11] [12] (Fig. 1a) . HNG co-cultures are a useful bioplatform to study basic disease mechanisms and drug efficacy as human primary neuronal cultures do not culture well in the absence of glial cells ( [9] [10] [11] [12] ; unpublished observations). At 2.5 weeks, HNG cells displayed approximately equal populations of neurons and glial cells [10] . CV-1 cells, derived from a simian kidney epithelial cell line and used widely as a host for HSV-1 proliferation studies were obtained from the American Type Culture Collection and cultured according to the supplier's instructions (ATCC; CCL-70; ATCC, Manassas, Virginia, USA). A low passage 3X plaque purified HSV-1 strain 17 syn + [15] , was added at time '0' at a multiplicity of infection ratios of 5 : 1 or 10 : 1 (HSV-1 virus particle-to-HN cell ratio) as described earlier [3] . HNG cell morphology was examined using the phase contrast microscopy at 0, 24, 48 and 72 h post HSV-1 infection using a Nikon Diaphot 200 microscope (Nikon Inc., Garden City, New York, USA).
CV-1 cell-based antiviral assay
HSV-1 strain 17Syn + was separately pre-incubated with differing concentrations (5 or 100 mM) of Ab42 or Ab42s (scrambled) peptide in approximately 200 ml at 371C for 1 h [3, 15] . Following peptide pre-treatment, 1X Dulbecco's modified Eagle's medium (Cellgro, Mediatech Inc., Manassas, Virginia, USA) containing 10% FBS and anti-HSV-1 human IgG was added to the approximately 200 ml volumes to a final volume of 2 ml. Each was added to an individual well of a six well-plate of near confluent (80%) monolayer CV-1 cells. An additional control was pre-incubated in which Ab42 or Ab42s peptide was replaced with 1X Dulbecco's modified Eagle's medium; these were plated in triplicate and incubated for 72 h at 371C and 5% CO 2 . CV-1 cells were fixed with 10% formaldehyde, washed, stained with crystal violet (Hucker's modified solution diluted 1 : 10 with 20% ethanol and 80% H 2 0) and plaques were counted [3, 15] .
RNA extraction, quality control and Northern dot blot analysis
Total RNA was extracted at 0 time and at 48 h after HSV-1 infection as these time points were earlier shown to exhibit significant differences both at the morphological and molecular level [3] . At 0 time and 48 h post-HSV-1 treatment HNG cells were rapidly transferred into 1 ml ice-cold TRIzol reagent (Invitrogen) and total RNA was extracted as described earlier [3, 10] . RNA quality was determined using an Agilent Bioanalyzer 2100 (Lucent Technologies and Caliper Technologies, Palo Alto, California, USA) and electropherograms were generated for each total RNA sample [3, [9] [10] [11] . As a quality control index, if 28S/18S ratios were larger than 1.4 and A 260/280 Z 2.1 (indicating high total RNA spectral quality), the samples were used for Northern dot blot analysis [3, [9] [10] [11] [12] . Samples were analyzed individually or as pooled samples. There were no significant differences in the total RNA yield or RNA spectral quality between the control and HSV-1 infected HNG cells.
Real-time quantitative PCR for HSV-1 DNA polymerase HSV-1 DNA polymerase was analyzed in total RNA samples using a One-Step RT-PCR kit (Invitrogen) using the forward and reverse primers 5 0 -CATCACCGACCC GGAGAGGGAC-3 0 and 5 0 -GGGCCAGGCGCTTGTT GGTGTA-3 [2, 16] . The fluorescent probe sequence 5 0 -6FAM-CCGCCGAACTGAGCAGACACCCGCGC-BHQ-1-3 0 was further used to quantify HSV-1 DNA polymerase signal levels as described earlier [2, 16] . The miRNAs arrays (LC Sciences, Houston, Texas, USA) were probed with total small miRNAs isolated at 0 and 48 h from control or HSV-1 infected HNG cells. Specific miRNAs showing strong hybridization signals were studied further and subjected to Northern dot blot analysis as described earlier [3, 10] .
Statistical analysis and data interpretation
All statistical procedures for miRNA and Northern abundance were analyzed using a two-way factorial analysis of variance (P) using programs and procedures in the SAS language (Statistical Analysis Institute, Cary, North Carolina, USA) and as described earlier by our group [10] . Only P values of less than 0.05 (analysis of variance) were considered to be statistically significant. 
Results
Changes in HNG cell morphology accompany HSV-1 infection; effects of ACV, Ab42 and Ab42s peptides Control HNG cells (uninfected, untreated) in primary culture exhibited a progressive increase in cell body number and neurite extensions, and after 2.5 weeks of culture exhibited about equal populations of neurons and glial ( Fig. 1a and b) [11, 12] . In contrast, dramatic changes in HNG cell culture morphology were observed 48 h post-HSV-1 infection typically showing a heterogeneous 'blebbing' and hypotrophy as HSV-1 infection progressed from 0 to 48 h ( Fig. 1c and d) . HNG cells infected with HSV-1 for 48 h exhibited extremely distorted cell morphology to the extent that many HNG cell bodies disappeared (data not shown). HNG cells treated with HSV-1 and ACV (30 mM) or Ab42 peptide (100 mM) exhibited protection from morphological change (Fig. 1e-h,  respectively) . Importantly, HNG cells treated with the non-bioactive scrambled Ab42s elicited no protection from the effects of HSV-1 infection (Fig. 1i and j) .
Detection of HSV-1 DNA polymerase using RT-PCR To further ascertain the antiviral actions of Ab42 peptide we assayed for HSV-1 DNA polymerase abundance in HNG cells and the results are shown in Table 1 . Consistent with our findings on changes in HNG cell morphology (Fig. 1) , 0 copy number of HSV-1 DNA polymerase were found in control, ACV-treated or Ab42-treated HNG cells; there was no significant difference in the detectable abundance of HSV-1 DNA polymerase in HSV-1-infected HNG cells either in the presence or absence of Ab42s.
Antiviral activity of Ab42 peptide using CV-1 cell viral plaque assay
We further studied the inhibitory actions of Ab42 peptide of HSV-1 infection using a CV-1 cell-based viral plaque assay. Control (no peptide) gave an average number of plaques in CV-1 culture of 34.5; the presence of Ab42 peptide at 5 and 100 mM ambient concentration reduced the average number of plaques to 47 and 16% of control, respectively ( Table 2 ). The presence of Ab42s at 5 and 100 mM ambient concentration showed no anti-viral activity and the average number of plaque counts were not significantly different from controls (Table 2 ).
RNA quality control and changes in micro-RNA abundance
Both controls and HSV-1-treated HNG cells yielded total RNA samples with 28S/18S ratios larger than 1.4 and A 260/280 Z 2.1 indicating high spectral quality RNA. Analysis of miRNA panels displaying 911 control RNAs, small RNAs, and miRNA levels and Northern dot blot analysis (Fig. 2a-c) indicated that levels of miRNA-146a were consistently up-regulated 4.5-fold, 48 h after HSV-1 infection. No changes were observed in the abundance of a brain abundant miRNA-134. All miRNA levels were normalized against 5S RNA in each sample and against eight hybridization controls on the miRNA panels whose expression levels remained unchanged either before or after HSV-1 infection (Fig. 2d) [3] . In agreement with the results obtained using the phase contrast microscopy and morphological observations (Fig. 1) , miRNA array assay, Northern dot blot assay, HSV-1 DNA polymerase assay (Table 1) and CV-1 cell viral plaque assay ( Table 2 ) the presence of ACV or Ab42 peptide quenched the induction of miRNA-146a but had no effect on miRNA-134 and other miRNAs (data not shown) (Fig. 2e) . Importantly, the presence of a non-biologically active peptide control, Ab42s, had no significant effect on miRNA-146a being induced by HSV-1.
Discussion

HSV-1 infection of human neuronal-glial co-cultures
Human HNG cells are highly susceptible to infection through neuroinvasive viruses such as HSV-1, a 152 kB, linear, double-stranded DNA encoding approximately 74 genes encased in a 100 nM diameter icosahedral capsid [1, 3, 17] . Capsid glycoproteins interact with HNG host cell receptors to mediate viral entry and infectivity. Various strains of HSV-1, commonly detected in human nervous tissue, can be stratified into low-reactivation and highreactivation phenotypes; high phenotypic re-activators include HSV-1 strains 17Syn + and McKrae and exhibit high reactivation frequency when induced by physiological stress [1, 3, 15, 16] . As expected, an infection of HSV-1 (17Syn +) in HNG cells produced a typical progressive loss of processes and cell rounding or hypertrophy (Fig. 1) that have been characterized earlier [1] [2] [3] .
Effects of Ab42 on expression of HSV-1 DNA polymerase HSV-1 DNA polymerase encodes a DNA copying enzyme essential for replication of HSV-1; therefore detection of HSV-1 DNA polymerase can be used as a marker for the success of HSV-1 infectivity [15] [16] [17] . This activity was significantly quenched in the presence of ACV and Ab42 peptide. Interestingly, Ab42 peptides, as central mediators of Alzheimer's disease neuropathology, tend to adsorb a wide variety of intracellular and extracellular ligands as they aggregate in Alzheimer Ab42 peptide-enriched senile plaque formations. These results further suggest that a natural increase in Ab42 peptide abundance to a perceived viral infection could be mediated by the brain's innate immune system leading to a pathogenic inflammatory response.
HSV-1 infection of CV-1 cells
CV-1 cells, epithelial cells widely used as a host for HSV-1 proliferation and viral quantitation assay were used to study the effects of ACV and Ab42 peptide in a nonneural cell type. That HSV-1-infected cells treated with ACV or Ab42 peptides were again similar to uninfected control HNG cells underscores the potent anti-viral plaque-inducing properties of both ACV and Ab42 peptides.
Regulation of miRNA-146a in HSV-1-infected HNG cells
The miRNAs are regulatory RNAs acting at the posttranscriptional level, which play critical roles in physiological Ab42s is a scrambled Ab42 peptide with no known biological activity; all HNG cell wells contained HSV-1 ± Ab42 or Ab42s peptides. HSV
and patho-physiological processes. An inducible, mouse and human brain abundant miRNA-146a has been implicated as a negative regulator of the innate immune, inflammatory and anti-viral pathway responses in several human diseases including Alzheimer's and prion disease [8] [9] [10] [11] [12] 18] . Specifically, miRNA-146a up-regulation is associated with down-regulation of complement factor H, an important repressor of the complement signaling cascade [3, [9] [10] [11] [12] . Interestingly, Kaposi's sarcoma-associated herpes virus, Epstein-Barr virus and vesicular stomatitis virus have each been shown to up-regulate host miRNA-146a, suggesting a broad role for miRNA-146a in the regulation of anti-viral immunity [13, [18] [19] [20] [21] . In addition to host miRNAs, HSV-1 has been reported to induce specific viral miRNAs, the functions of which are not completely understood [19, 22] .
Several important questions remain. The mechanism of how Ab42 peptides quench HSV-1-induced changes in HNG cells could operate by multiple interrelated mechanisms. Our results showed maximal effects of soluble Ab42 peptide at 100 mM ambient concentrations, which is in vast excess to what would be normally present in any stressed HNG or Alzheimer-affected brain cell. Other biophysical forms of Ab42 peptide such as cylindrical Ab42 beta-sheets, nanotubes or fibrils need to be examined for anti-HSV-1 efficacy. By virtue of their amino acid sequence Ab42 peptides are intensely hydrophobic and may simply adsorb HSV-1, and hence sequester HSV-1, to effectively 'immobilize' HSV-1 bioactivity or may destroy the virus via membrane destabilization effects. HSV-1-infected cells produce significant quantities of noninfectious, non-DNA-containing light particles (L-particles) comprised of viral envelope and tegument proteins, and HSV-1 and L-particles are both integrally associated with Ab42 peptide deposits in Alzheimer brains [6, 7] . Alternately, soluble Ab42 peptide could adsorb to HNG outer cell surfaces to inhibit HSV-1 glycoprotein-mediated viral . Individual miRNA panels were probed with total miRNA obtained from control and HSV-1 infected HNG cells at 48 h and results were compared as perviously described [9] [10] [11] [12] . Identity of all miRNAs and their coordinates ( Fig. 2a-c ; rows a-e) can be found at www.lcsciences.com [3, 10] . Independent confirmation of 5S RNA, miRNA-134 and miRNA-146a levels using Northern dot blot analysis as previously described [3, 10] (d). No change in the abundance of a control miRNA-134 in any of the samples analyzed was noted. All miRNA levels were normalized against the abundance of 5S RNA in each sample, and also against eight hybridization controls on the miRNA panels whose expression levels remained unchanged either before or after HSV-1 infection [3] . Signal quantitation for miRNA Northern dot blots from (d) compared to 5S RNA in the same sample are shown in (e). On the miRNA dot blot panels in (d) 5S RNA was loaded at one twentieth the concentration of miRNA-134 and miRNA-146a; N = 4; significance over HSV-1-untreated controls; *P < 0.01 (ANOVA). attachment and entry, or there may be a combination of both biophysical events. Recently, Ab42 peptides have been shown to evoke potent anti-microbial activities [23] . Although the basis for this bioactivity is not known both antimicrobial and antiviral properties of Ab42 peptides may have common or interrelated bio-protective mechanisms [23, 24] . It is conceivable that evolutionary, innate immune or inflammatory adaptations incorporated by human brain cells to successfully evade HSV-1 attack, in part through the up-regulation of Ab42 peptides, could also trigger processes that lead to chronic, neurodegenerative diseases.
Conclusion
We show a protection against induced pathological changes in HSV-1-infected HNG cells using an established antiviral acycloguanosine ACV and soluble Ab42 peptides. Although ACV acts as a 'classical' inhibitor of HSV-1 DNA polymerase and hence viral proliferation, the intensely hydrophobic and 'sticky' Ab42 peptide may adsorb and sequester HSV-1, preventing active HNG cell infection. As do several other neuroinvasive viruses, HSV-1 up-regulates miRNA-146a; however, in the presence of either ACV or Ab42 peptide miRNA-146a upregulation was not observed. Non-pathological effects of Ab42 peptides in the brain and alternative roles for Ab42 peptides in Alzheimer's disease are beginning to be appreciated [23] [24] [25] . Anti-viral drug, peptide or antimiRNA strategies, or their combination, could be useful in blocking the success of HSV-1 infection.
